Table 1B.
Factors | ABA | ZT | GA1 | |
---|---|---|---|---|
ng g−1 FW | ng g−1 FW | ng g−1 FW | ||
Treatment (T) | Control | 98.2a | 16.1c | 0.52c |
30 mgL−1 BAP | 97.4a | 16.2c | 0.53bc | |
60 mgL−1 BAP | 90.0d | 16.9a | 0.58a | |
90 mgL−1 BAP | 93.9c | 16.4b | 0.55ab | |
10 mgL−1 GA3 | 95.1bc | 16.3bc | 0.56ab | |
20 mgL−1 GA3 | 95.2b | 16.3bc | 0.58a | |
30 mgL−1 GA3 | 95.5b | 16.2bc | 0.55b | |
LSD T (P ≤ 0.05) | 1.27 | 0.22 | 0.023 | |
Genotype (G) | FD51-5 | 62.0e | 19.1b | 0.70b |
PRI red | 54.1f | 22.9a | 0.84a | |
Sante | 100.7c | 14.3d | 0.47c | |
FD73-49 | 95.1d | 17.0c | 0.45cd | |
FD69-1 | 122.6b | 12.7e | 0.44d | |
FD8-1 | 135.9a | 12.2f | 0.39e | |
LSD G (P ≤ 0.05) | 1.18 | 0.20 | 0.021 | |
Storage period (SP) | 1 Week | 125.7a | 9.7a | 0.59a |
3 Week | 64.4b | 23.0b | 0.51b | |
LSD SP (P ≤ 0.05) | 0.68 | 0.12 | 0.012 | |
LSD T × G (P ≤ 0.05) | NS | NS | NS | |
LSD T × SP (P ≤ 0.05) | NS | NS | NS | |
LSD G × SP (P ≤ 0.05) | 1.67 | 0.29 | 0.030 | |
LSD T × G × SP (P ≤ 0.05) | NS | NS | NS |
NS, non-significant at P ≤ 0.05.
Treatment means sharing same letter differ non-significantly.
ABA, abscisic acid; GA1, gibberellin A1; BAP, benzylaminopurine; GA3, gibberellic acid; LSD, least significant difference.